BE2012C025I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C025I2
BE2012C025I2 BE2012C025C BE2012C025C BE2012C025I2 BE 2012C025 I2 BE2012C025 I2 BE 2012C025I2 BE 2012C025 C BE2012C025 C BE 2012C025C BE 2012C025 C BE2012C025 C BE 2012C025C BE 2012C025 I2 BE2012C025 I2 BE 2012C025I2
Authority
BE
Belgium
Application number
BE2012C025C
Other languages
French (fr)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C025(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BE2012C025I2 publication Critical patent/BE2012C025I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
BE2012C025C 2004-02-25 2012-06-07 BE2012C025I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof
PCT/JP2005/003422 WO2005080384A2 (en) 2004-02-25 2005-02-23 Benzimidazole derivative and use as aii receptor antagonist

Publications (1)

Publication Number Publication Date
BE2012C025I2 true BE2012C025I2 (en) 2024-08-08

Family

ID=34858222

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C025C BE2012C025I2 (en) 2004-02-25 2012-06-07

Country Status (34)

Country Link
US (3) US7157584B2 (en)
EP (3) EP2119715B1 (en)
JP (2) JP4256852B2 (en)
KR (1) KR101080029B1 (en)
CN (2) CN100503605C (en)
AR (2) AR047972A1 (en)
AT (2) ATE370136T1 (en)
AU (1) AU2005214271B8 (en)
BE (1) BE2012C025I2 (en)
BR (2) BRPI0507984B8 (en)
CA (1) CA2557538C (en)
CY (5) CY1107008T1 (en)
DE (3) DE602005002030T2 (en)
DK (3) DK1718641T3 (en)
ES (3) ES2293552T3 (en)
FR (1) FR12C0034I2 (en)
HR (3) HRP20070510T3 (en)
HU (1) HUS1200008I1 (en)
IL (1) IL177533A (en)
LU (1) LU91962I2 (en)
MA (1) MA28478B1 (en)
ME (2) ME01089B (en)
MY (1) MY142807A (en)
NL (1) NL300802I2 (en)
NO (2) NO332344B1 (en)
NZ (1) NZ549755A (en)
PL (3) PL2119715T3 (en)
PT (3) PT1857457E (en)
RS (3) RS50537B (en)
RU (2) RU2369608C2 (en)
SI (3) SI1857457T1 (en)
TW (1) TWI336702B (en)
WO (1) WO2005080384A2 (en)
ZA (1) ZA200607241B (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
CN102049048B (en) 2004-12-24 2013-12-25 西芬克斯医药有限公司 Method of treatment or prophylaxis
JP4465469B2 (en) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 Interleukin 13 as a cardiovascular disease marker
US20090054502A1 (en) * 2005-03-30 2009-02-26 Takeda Pharmaceutical Company Limited Benzimidazole Derivative and Use as Angiotensin II Antagonist
WO2007097452A1 (en) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Medical blister package
WO2007097451A1 (en) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Pharmaceutical package
CA2646379C (en) 2006-03-20 2014-12-23 The University Of Queensland Method of treatment or prophylaxis inflammatory pain
ES2381507T3 (en) * 2006-09-25 2012-05-28 Takeda Pharmaceutical Company Limited Medicinal container
WO2008123536A1 (en) * 2007-03-28 2008-10-16 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
JP2009062296A (en) * 2007-09-05 2009-03-26 Fujifilm Corp Method for producing carboxylic acid ester compound
US20110038898A1 (en) * 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
MX2011001150A (en) * 2008-07-31 2011-03-29 Takeda Pharmaceutical Solid pharmaceutical composition.
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
CA2741125A1 (en) * 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101931209B1 (en) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
WO2012090043A1 (en) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
US9233954B2 (en) 2011-01-20 2016-01-12 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of Azilsartan, preparation method and use thereof
US9233955B2 (en) 2011-02-08 2016-01-12 Jubilant Life Sciences, Ltd. Process for the preparation of azilsartan medoxomil
CN102138899B (en) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 Olmesartan liposome solid preparation
RS55056B1 (en) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
CN102827153B (en) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 Crystal formation of Azilsartan and preparation method thereof
CN102351853B (en) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 Azilsartan medoxomil compound, preparation method and medicinal composition thereof
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
BR112014014527A2 (en) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinations of azilsartan and chlorotalidone to treat hypertension in black patients
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
CN104039779B (en) * 2012-01-14 2016-08-24 广东东阳光药业有限公司 Crystal formation of Azilsartan potassium and preparation method thereof and application thereof
US20150011774A1 (en) * 2012-02-02 2015-01-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (en) * 2012-04-19 2013-10-30 Zentiva, K.S. Process for preparing extremely pure potassium salt of azilsartan medoxomil
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
WO2014009969A2 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Novel polymorphs of azilsartan
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
EP2925753A4 (en) 2012-08-27 2017-02-15 Hetero Research Foundation Novel polymorphs of azilsartan medoxomil
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CZ305318B6 (en) * 2012-09-26 2015-07-29 Zentiva, K.S. Process for preparing extremely pure azilsartan medoxomil potassium salt
CN105237527B (en) * 2012-09-28 2018-03-06 武汉朗来科技发展有限公司 Benzimidizole derivatives and preparation method thereof and medical usage
AU2013329251A1 (en) * 2012-10-09 2015-04-30 Avery Dennison Corporation Adhesives and related methods
CN103910720A (en) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 Novel crystal form of azilsartan medoxomil and preparation method thereof
CN105153141B (en) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 Benzimidizole derivatives and preparation method thereof and medical usage
JP6281735B2 (en) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 Method for evaluating therapeutic agent for acute heart failure and method for producing acute heart failure model
RU2535004C1 (en) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Method of treatment intervertebral disk disease in dogs
RU2535005C1 (en) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Method of treatment of intervertebral disk diseases in dogs
CN104812752B (en) * 2013-10-12 2016-09-28 杭州领业医药科技有限公司 Crystal form of azilsartan medoxomil and preparation method thereof
CN105949183B (en) * 2013-10-12 2019-02-22 杭州领业医药科技有限公司 Crystal form of Azilsartan and preparation method thereof
CN104774197B (en) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 A kind of preparation method of benzimidizole derivatives
CN104774196B (en) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 A kind of preparation method of benzimidizole derivatives
CN105079815A (en) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 A kind of azilsartan medoxomil potassium composition and preparation method thereof
CN104016974A (en) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 Azilsartan medoxomil intermediates and synthetic methods thereof, as well as synthetic method of azilsartan medoxomil
CZ2014702A3 (en) 2014-10-15 2016-04-27 Zentiva, K.S. Process for preparing extremely pure azilsartan
CN105622595A (en) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 Novel preparation method of azilsartan medoxomil sylvite and its intermediate
CN105753854A (en) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 New preparation method of azilsartan kamedoxomil
US9708306B2 (en) 2015-03-18 2017-07-18 Wuhan Ll Science And Technology Development Co., Ltd Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
CN106032378B (en) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 New A RB compound and application thereof
CN104803998B (en) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 A kind of method for reducing impurity content
JP2018521077A (en) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーTakeda GmbH PDE4 inhibitor for the treatment of diabetic nephropathy
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (en) * 2016-11-30 2021-04-07 株式会社トクヤマ Manufacturing method of azilsartan
CN109071519A (en) * 2016-01-28 2018-12-21 株式会社德山 Azilsartan and its manufacturing method
CN105628824B (en) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 About the method for material in a kind of high effective liquid chromatography for measuring Azilsartan raw material
CN112110909A (en) * 2016-05-20 2020-12-22 武汉朗来科技发展有限公司 Compound, preparation method, composition and application thereof
CN105770876B (en) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 Purposes of the ulinastatin in preparation treatment chronic prostatitis drug
RU2623082C1 (en) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for arterial rigidity correction in patients with rheumatoid arthritis
EP3461822B1 (en) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Crystalline form of chemical compound, and preparation method, composition, and application thereof
RU2634272C1 (en) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Composition with desamino-arginine vasotocin for parenteral introduction and method for its production
CN106074416A (en) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 A kind of preparation method of Azilsartan potassium salt dispersible tablet
FI3524250T3 (en) * 2016-10-08 2025-08-29 Wuhan Ll Science & Technology Development Co Ltd Pharmaceutical composition comprising a neutral endopeptidase (nep) inhibitor and an azilsartan ester derivative and use thereof for treating cardiovascular diseases
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN110237071B (en) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 Pharmaceutical preparation and use thereof
CN110237072B (en) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 Process for preparing pharmaceutical composition
JP2021528735A (en) 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドAstraZeneca UK Limited Treatment of hypertension with angiotensin II receptor blocker pharmaceutical composition
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
KR20200057662A (en) 2018-11-16 2020-05-26 엠에프씨 주식회사 The derivative compounds of Azilsartan, intermediates thereof, preparation thereof and pharmaceutical composition comprising the same
US11912688B2 (en) 2019-02-15 2024-02-27 Tohoku University 1, 3-dioxolane derivative
KR102220011B1 (en) 2020-05-15 2021-02-25 대봉엘에스 주식회사 Method for preparing azilsartan with environment-friendly solvent, and key intermediate compounds thereof
CN113912580B (en) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 Method for purifying 4- (hydroxymethyl) -5-methyl- [1,3] dioxol-2-one
TW202340183A (en) 2021-12-28 2023-10-16 日商亞克醫藥股份有限公司 Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition
EP4606374A1 (en) * 2022-11-24 2025-08-27 Shanghai Aurora Biotechnology Co., Ltd. Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (en) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd Organic electrolyne secondary battery
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IS1756B (en) 1991-02-21 2000-12-28 Sankyo Company Limited Analogue method for the preparation of 1-biphenylmethylimidazole derivatives
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
RU2117668C1 (en) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Oxazolidone derivative or its pharmacologically acceptable salts, pharmaceutical composition, method of treatment
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
JP2787539B2 (en) * 1993-02-26 1998-08-20 松森  昭 Agent for preventing or treating viral diseases
FR2708612B1 (en) * 1993-08-05 1996-03-01 Roussel Uclaf New bicyclic derivatives of imidazole, their preparation process, the new intermediates obtained, their application as medicaments and the pharmaceutical compositions containing them.
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
DE19707628A1 (en) * 1997-02-26 1998-08-27 Merck Patent Gmbh Oxazolidinones
CN1441794A (en) 2000-07-13 2003-09-10 武田药品工业株式会社 lipid-rich plaque reducer
CA2468827A1 (en) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
AU2003202488A1 (en) 2002-01-11 2003-07-30 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (en) 2005-07-15 2009-11-11 本田技研工業株式会社 Automotive door checker

Also Published As

Publication number Publication date
TWI336702B (en) 2011-02-01
CY1109610T1 (en) 2014-08-13
ME01643B (en) 2010-05-07
ME01089B (en) 2013-03-20
BRPI0507984A (en) 2007-07-24
CN100503605C (en) 2009-06-24
CY2012016I1 (en) 2016-12-14
EP1857457B1 (en) 2009-08-19
AR047972A1 (en) 2006-03-15
KR101080029B1 (en) 2011-11-04
AU2005214271A2 (en) 2005-09-01
HK1098472A1 (en) 2007-07-20
DE602005002030D1 (en) 2007-09-27
PL1857457T3 (en) 2009-12-31
SI1857457T1 (en) 2010-01-29
TW200530227A (en) 2005-09-16
CN1946717A (en) 2007-04-11
RS50537B (en) 2010-05-07
HK1115118A1 (en) 2008-11-21
AR094588A2 (en) 2015-08-12
PL1718641T3 (en) 2008-01-31
CN101381366A (en) 2009-03-11
AU2005214271B8 (en) 2011-03-03
JP4256852B2 (en) 2009-04-22
WO2005080384A3 (en) 2006-09-28
CN101381366B (en) 2011-06-15
MY142807A (en) 2011-01-14
CY2012016I2 (en) 2016-12-14
IL177533A (en) 2010-12-30
FR12C0034I1 (en) 2012-06-15
ZA200607241B (en) 2008-04-30
DK2119715T3 (en) 2012-09-10
RS52376B (en) 2012-12-31
NO332344B1 (en) 2012-09-03
ES2331209T3 (en) 2009-12-23
KR20070020411A (en) 2007-02-21
CY2012015I2 (en) 2016-12-14
ATE440095T1 (en) 2009-09-15
US20050187269A1 (en) 2005-08-25
RU2006133898A (en) 2008-03-27
RU2501798C2 (en) 2013-12-20
WO2005080384A9 (en) 2006-11-30
ES2388945T3 (en) 2012-10-22
EP2119715A1 (en) 2009-11-18
RU2009115498A (en) 2010-10-27
DE602005002030T2 (en) 2008-05-08
AU2005214271A1 (en) 2005-09-01
ATE370136T1 (en) 2007-09-15
NO2012017I2 (en) 2012-11-09
IL177533A0 (en) 2006-12-10
NL300802I2 (en) 2016-05-18
CA2557538A1 (en) 2005-09-01
DK1857457T3 (en) 2009-12-21
US20090270464A1 (en) 2009-10-29
EP2119715B1 (en) 2012-05-30
DE602005016162D1 (en) 2009-10-01
EP1857457A2 (en) 2007-11-21
HRP20090593T1 (en) 2010-03-31
AU2005214271B2 (en) 2011-02-24
US20060281795A1 (en) 2006-12-14
RU2369608C2 (en) 2009-10-10
DE122012000018I1 (en) 2012-06-06
EP1857457A3 (en) 2007-12-05
NO20064251L (en) 2006-11-22
US7572920B2 (en) 2009-08-11
BRPI0507984B8 (en) 2023-03-21
LU91962I2 (en) 2012-05-21
JP2009137974A (en) 2009-06-25
PT1718641E (en) 2007-11-15
RS51137B (en) 2010-10-31
FR12C0034I2 (en) 2013-01-11
US7157584B2 (en) 2007-01-02
HUS1200008I1 (en) 2017-06-28
EP1718641A2 (en) 2006-11-08
SI2119715T1 (en) 2012-10-30
ES2293552T3 (en) 2008-03-16
CA2557538C (en) 2010-08-17
BR122012009489B8 (en) 2023-03-21
BR122012009489B1 (en) 2019-02-19
PT2119715E (en) 2012-09-03
CY1113084T1 (en) 2016-04-13
PL2119715T3 (en) 2012-10-31
NZ549755A (en) 2009-04-30
SI1718641T1 (en) 2007-12-31
CY2012015I1 (en) 2016-12-14
US7875637B2 (en) 2011-01-25
JP2005272451A (en) 2005-10-06
DK1718641T3 (en) 2007-12-17
WO2005080384A2 (en) 2005-09-01
NO2012017I1 (en) 2012-11-26
EP1718641B1 (en) 2007-08-15
CY1107008T1 (en) 2012-09-26
HRP20070510T3 (en) 2007-12-31
PT1857457E (en) 2009-09-23
BRPI0507984B1 (en) 2018-07-03
MA28478B1 (en) 2007-03-01
HRP20120667T1 (en) 2012-09-30
HRP20120667T2 (en) 2012-11-30

Similar Documents

Publication Publication Date Title
BE2024C508I2 (en)
BE2022C549I2 (en)
BE2023C542I2 (en)
BE2021C001I2 (en)
BE2020C513I2 (en)
BE2020C517I2 (en)
BE2019C540I2 (en)
BE2019C523I2 (en)
BE2019C506I2 (en)
BE2019C548I2 (en)
BE2018C045I2 (en)
BE2020C525I2 (en)
BE2017C063I2 (en)
BE2017C027I2 (en)
BE2017C023I2 (en)
BE2017C002I2 (en)
BE2016C067I2 (en)
BE2016C014I2 (en)
BE2015C041I2 (en)
BE2015C038I2 (en)
BE2015C014I2 (en)
BE2015C015I2 (en)
BE2015C066I2 (en)
BE2014C071I2 (en)
BE2014C064I2 (en)